Doximity is trading at $28.99, up 4.69%, with no clear company-specific catalyst identified for the October 8 gain.
- Recent coverage mainly concerns securities-lawsuit notices about a class period ending May 13, 2026; those notices do not establish a reason for this session’s rise.
- The Nasdaq was down 0.60%, so the broader market’s direction does not explain Doximity’s gain. The cause remains unclear.